High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease
| Autor: | Roger S. Blumenthal, M. Dominique Ashen, Navin K. Kapur |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system Endocrinology Diabetes and Metabolism Disease Review Bioinformatics law.invention chemistry.chemical_compound Framingham Heart Study High-density lipoprotein Randomized controlled trial law Risk Factors Internal medicine Medicine Animals Humans high density lipoprotein cholesterol (HDL-C) Pharmacology (medical) coronary Hypolipidemic Agents Clinical Trials as Topic Cholesterol business.industry Reverse cholesterol transport Cholesterol HDL Public Health Environmental and Occupational Health nutritional and metabolic diseases Hematology General Medicine Coronary heart disease reverse cholesterol transport Clinical trial Endocrinology chemistry Cardiovascular Diseases lcsh:RC666-701 Drug Therapy Combination Smoking Cessation lipids (amino acids peptides and proteins) atherosclerosis Cardiology and Cardiovascular Medicine business |
| Zdroj: | Vascular Health and Risk Management, Vol Volume 4, Pp 39-57 (2008) Vascular Health and Risk Management |
| ISSN: | 1178-2048 |
| Popis: | Navin K Kapur, Dominique Ashen, Roger S BlumenthalDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USAAbstract: Since the pioneering work of John Gofman in the 1950s, our understanding of high density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have demonstrated an inverse relationship between HDL-C and one’s risk of developing CHD. Over the past two decades, preclinical research has gained further insight into the nature of HDL-C metabolism, specifically regarding the ability of HDL-C to promote reverse cholesterol transport (RCT). Recent attempts to harness HDL’s ability to enhance RCT have revealed the complexity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving therapeutic target in the management of cardiovascular disease.Keywords: high density lipoprotein cholesterol (HDL-C), coronary, atherosclerosis, reverse cholesterol transport |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|